Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial
- 31 May 1999
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 137 (5) , 786-791
- https://doi.org/10.1016/s0002-8703(99)70400-x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- TNK–Tissue Plasminogen Activator Compared With Front-Loaded Alteplase in Acute Myocardial InfarctionCirculation, 1998
- A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- A Comparison of Reteplase with Alteplase for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- TNK-Tissue Plasminogen Activator in Acute Myocardial InfarctionCirculation, 1997
- New Variant of Human Tissue Plasminogen Activator (TPA) With Enhanced Efficacy and Lower Incidence of Bleeding Compared With Recombinant Human TPACirculation, 1995
- Stroke After ThrombolysisCirculation, 1995
- A Randomized Trial of Recombinant Staphylokinase Versus Alteplase for Coronary Artery Patency in Acute Myocardial InfarctionCirculation, 1995
- A faster-acting and more potent form of tissue plasminogen activator.Proceedings of the National Academy of Sciences, 1994
- Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsPublished by Elsevier ,1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993